Lupin Pharmaceuticals Inc. recalls Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 6818
Recalled November 27, 2024 · FDA recall D-0052-2025 · Lupin Pharmaceuticals
Hazard
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor · FDA Class II
Units
112,770 bottles
Sold at
Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide.
Description
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
Product
Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India
Manufacturer(s)
Lupin Pharmaceuticals Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →